NEBIBE VAROL
Author(s)
Varol N1, Divino V2, Hallinan S2, Dekoven M2, Lee WC2, Reaney MD1
1Eli Lilly and Company, Windlesham, Surrey, UK, 2IMS Health, Alexandria, VA, USA
OBJECTIVES: To evaluate treatment patterns of Type 2 diabetes (T2DM) patients initiating glucagon-like peptide-1 receptor agonists (GLP-1) in Canada. METHODS: Adult T2DM patients initiating a GLP-1 between January 2010 and December 2011 were identified using the IMS retail pharmacy database (LRx). Initiation was termed ‘index date’
Conference/Value in Health Info
2014-05, ISPOR 2014, Palais des Congres de Montreal
Value in Health, Vol. 17, No. 3 (May 2014)
Code
PDB129
Topic
Health Service Delivery & Process of Care
Topic Subcategory
Prescribing Behavior
Disease
Diabetes/Endocrine/Metabolic Disorders